Enanta Pharmaceuticals (ENTA) Capital Expenditures Growth (1y) (2013 - 2025)
Enanta Pharmaceuticals (ENTA) Capital Expenditures Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -281.70% |
| Jun 30, 2025 | 104.44% |
| Mar 31, 2025 | 282.88% |
| Dec 31, 2024 | 406.68% |
| Sep 30, 2024 | 183.01% |
| Jun 30, 2024 | -157.41% |
| Mar 31, 2024 | 44.02% |
| Dec 31, 2023 | 9,480.00% |
| Sep 30, 2023 | -542.67% |
| Jun 30, 2023 | 2,454.20% |
| Mar 31, 2023 | 1,154.69% |
| Dec 31, 2022 | -89.13% |
| Jun 30, 2022 | 174.84% |
| Mar 31, 2022 | -1.54% |
| Dec 31, 2021 | -75.53% |
| Jun 30, 2021 | -267.37% |
| Mar 31, 2021 | 134.30% |
| Dec 31, 2020 | -61.48% |
| Sep 30, 2020 | -105.69% |
| Jun 30, 2020 | 113.19% |